Occurrence and Prognosis for the Thrombosis in the Drug-Eluting Stents and Bare-Metal Stents

약물 용출 스텐트와 일반 금속 스텐트에서 혈전증에 대한 발생과 예후

  • 김인수 (동신대학교 방사선학과) ;
  • 최남길 (동신대학교 방사선학과) ;
  • 장성주 (동신대학교 방사선학과) ;
  • 한재복 (동신대학교 방사선학과) ;
  • 장영일 (광양보건대학교 방사선과)
  • Received : 2012.04.27
  • Accepted : 2012.05.31
  • Published : 2012.07.28


Drug-eluting stents (DES) have significantly reduced in-stent restenosis, compared to bare-metal stents (BMS). However, there remains concern for the increased risk of stent thrombosis (ST) associated with DES. The present study sought to evaluate the incidence, clinical characteristics and outcome of ST in patients with acute myocardial infarction (MI) during a 1-year follow-up. 80 patients who developed ST were divided into 2 groups according to stent type: group I (DES-ST, n = 57 ) and group II (BMS-ST, n = 23 ). There were no differences between group I and II in the overall incidence of ST (2.7% vs. 4.3%, p=0.064) and in the incidence of each type of ST: acute ST (8.8% vs. 2.3%), subacute ST (50.9% vs. 60.9%), late ST (19.3% vs. 8.7%), and very late ST (21.1% vs. 17.4%) (p=0.605). Predictors of 1-year mortality were the occurrence of ST (OR 8.12, 95% CI 2.83-23.61, p<0.001), left ventricular ejection fraction<40% (OR 6.41, 95% CI 2.42-16.96, p<0.001), and age${\geq}$75 years (OR 4.98, 95% CI 1.95-12.74, p=0.001).


Drug-eluting stents;Stent thrombosis;Percutaneous Coronary Intervention


  1. J. E. Sousa, M. A. Costa, and A. Abizaid, "Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study," Circulation, Vol.103, pp.192-195, 2001.
  2. J. W. Moses, M. B. Leon, and J. J. Popma, "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery," N Engl J Med, Vol.349, pp.1315-1323, 2003.
  3. J. E. Sousa, M. A. Costa, and A. G. Sousa, "Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries," Circulation, Vol.107, pp.381-383, 2003.
  4. G. W. Stone, S. G. Ellis, and D. A. Cox, "One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent," Circulation, Vol.109, pp.1942-1947, 2004.
  5. M. C. Morice, P. W. Serruys, and J. E. Sousa, "A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization," N Engl J Med, Vol.346, pp.1773-1780, 2002.
  6. J. W. Moses, M. B. Leon, and J. J. Popma, "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery," N Engl J Med, Vol.349, pp.1315-1323, 2003.
  7. G. W. Stone, S. G. Ellis, and D. A. Cox, "A polymer-based, paclitaxelelutin stent in patients with coronary artery disease," N Engl J Med, Vol.350, pp.221-231, 2004.
  8. A. Colombo, J. Drzewiecki, and A. Banning, "Randomized study to assess the effectiveness of slow- and moderate-release polymerbased paclitaxel-eluting stents for coronary artery lesions," Circulation, Vol.108, pp.788-794, 2003.
  9. E. Schampaert, E. A. Cohen, and M. Schluter, "The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS)," J Am Coll Cardiol, Vol.43, pp.1110-1115, 2004.
  10. J. Schofer, M. Schluter, and A. H. Gershlick, "Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)," Lancet, Vol.362, pp.1093-1099, 2003.
  11. S. J. Park, Y. H. Kim, and B. K. Lee, "Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation," J Am Coll Cardiol, Vol.45, pp.351-356, 2005.
  12. I. S. Kim, J. B. Han, S. J. Jang, and Y. I. Jang, "The Study on the Independent Predictive Factor of Restenosis afterPercutaneous Coronary Intervention used Drug-Eluting Stent : Case on MDCT Calcium-Scoring Implementation Patient," 방사선기술학회지, Vol.33, No.1, pp.37-44, 2010.
  13. A. Jeremias, B. Sylvia, and J. Bridges, "Stent thrombosis after successful sirolimus-eluting stent implantation," Circulation, Vol.109, pp.1930-1932, 2004.
  14. D. W. Park and S. W. Park, "Stent thrombosis in the era of the drugeluting stent," Korean Circ J, Vol.35, pp.791-794, 2005.
  15. S. Park, G. R. Hong, H. S. Seo, and S. J. Tahk, "Stent thrombosis after successful drug-eluting stent implantation," Korean Circ J, Vol.35, pp.163-171, 2005.
  16. J. Daemen, H. M. Garcia-Garcia, and N. Kukreja, "The long-term value of sirolimusand paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus," Eur Heart J, Vol.28, pp.26-32, 2007.
  17. S. G. Ellis, A. Colombo, and E. Grube, "Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years," J Am Coll Cardiol, Vol.49, pp.1043-1051, 2007.
  18. R. Moreno, C. Fernandez, and R. Hernandez, "Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies," J Am Coll Cardiol, Vol.45, pp.954-959, 2005.
  19. E. Schampaert, J. W. Moses, and J. Schofer "Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses," Am J Cardiol, Vol.98, pp.36-41, 2006.
  20. D. E. Cutlip, S. Windecker, and R. Mehran, "Clinical end points in coronary stent trials: a case for standardized definitions," Circulation, Vol.115, No.17, pp.2344-2345, 2007.
  21. J. H. Moon, M. H. Jeong, and I. S. Kim, "The Frequency, Treatment and Clinical Outcomes of Stent Thrombosi after Use of TAXUSTM Stent," Korean Circ J, Vol.37, pp.641-646, 2007.
  22. A. Farb and A. B. Boam, "Stent thrombosis redux: the FDA perspective," N Engl J Med, Vol.356, pp.984-987, 2007.
  23. G. De Luca, G. Carbone, A. Maione, and G. Gregorio, "In-stent thrombosis after discontinuation of antiplatelet therapy 2 years after DES implantation: a case report," Int J Cardiol, Vol.116, pp.399-400, 2007.
  24. R. Artang and R. S. Dieter, "Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries," Am J Cardiol, Vol.99, pp.1039-1043, 2007.
  25. C. L. Grines, R. O. Bonow, and D. E. Jr Casey, "Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians," Catheter Cardiovasc Interv, Vol.69, pp.334-340, 2007.
  26. F. Burzotta, E. Romagnoli, and A. Manzoli, "The Outcome of PCI for stent-ThrombosIs MultIcentre Study (OPTIMIST): rationale and design of a multicenter registry," Am Heart J Vol.153, p.377, 2007.
  27. US Food and Drug Administration Public Health Web Notification, "FDA advises physicians of adverse events associated with Cordis Cypher coronary stents," T03-T71, 2003.
  28. I. Iakovou, T. Schmidt, and E. Bonizzoni, "Incidence, predictors, and outcome of thrombosis after successful implantation of drugeluting stents," JAMA, Vol.293, pp.2126-2130, 2005.
  29. J. Daemen, P. Wenaweser, and K. Tsuchida, "Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study," Lancet, Vol.369, pp.667-678, 2007.
  30. J. Oyabu, Y. Ueda, N. Ogasawara, K. Okada, A. Hirayama, and K. Kodama, "Angioscopic evaluation of neointima coverage: sirolimus drugeluting stent versus bare metal stent," Am Heart J, Vol.152, pp.1168-1174, 2006.
  31. H. W. Park, M. H. Jeong, and O. Y. Park, "The long-term clinical effects of heparin coated coronary stent," Korean Circ J, Vol.32, pp.773-780, 2002.
  32. W. Kim, M. H. Jeong, and K.S. Cha, "The effect of anti-oxidants (carvedilol and probucol) loaded stents in a porcine coronary restenosis model," Circ J, Vol.69, pp.101-106, 2005.
  33. W. Kim, M. H. Jeong, and Y. J. Hong, "The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab:$ReoPro^{(R)}$) coated stent in patients with acute myocardial infarction," Korean Circ J, Vol.34, pp.1063-1069, 2004.
  34. Y. J. Hong, M. H. Jeong, and W. Kim "Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries," Am J Cardiol, Vol.94, pp.1050-1054, 2004.
  35. O. Y. Park, M. H. Jeong, and J. H. Kim, "The inhibitory effects of a platelet glycoprotein IIb/IIIa receptor blocker-coated stent on neointima formation and inflammatory response in porcine coronary stent restenosis," Korean Circ J, Vol.33, pp.439-445, 2003.
  36. S. Y. Lim and M. H. Jeong, "Is heparin-coated stent effective in patients with acute myocardial infarction?," Korean Circ J, Vol.34, pp.537-539, 2004.
  37. W. Kim, M. H. Jeong, and K. H. Kim, "The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab-ReoPro) -coated stent in acute myocardial infarction," J Am Coll Cardiol, Vol.47, pp.933-938, 2006.
  38. S. Y. Lim, E. H. Bae, and M. H. Jeong "The effect of oral administration of alpha lipoic acid and alpha lipoic acid coated stent in porcine in-stent restenosis model," Korean Circ J, Vol.36, pp.495-502, 2006.
  39. P. W. Serruys, B. H. Strauss, H. M. van Beusekom, and W. J. van der Giessen, "Stenting of coronary arteries: has a modern Pandora' box been opened?," J Am Coll Cardiol, Vol.17, pp.143B-154B, 1991.